His main research concerns Immunology, Internal medicine, Pathology, Dermatomyositis and Myositis. Many of his studies involve connections with topics such as Polyneuropathy and Immunology. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Endocrinology, Surgery and Stiff person syndrome.
His work carried out in the field of Pathology brings together such families of science as Inflammation and CD8. His study in Dermatomyositis is interdisciplinary in nature, drawing from both Polymyositis, Autoimmune disease and Clinical trial. Marinos C. Dalakas usually deals with Myositis and limits it to topics linked to Disease and Intensive care medicine.
Marinos C. Dalakas mostly deals with Immunology, Pathology, Internal medicine, Antibody and Inclusion body myositis. His Immunology research is multidisciplinary, incorporating perspectives in Dermatomyositis and Myositis. The study of Pathology is intertwined with the study of Inflammation in a number of ways.
His biological study spans a wide range of topics, including Gastroenterology, Endocrinology, Surgery and Stiff person syndrome. Marinos C. Dalakas interconnects CD8 and Inflammatory myopathy in the investigation of issues within Inclusion body myositis. His Autoantibody research includes elements of Multiple sclerosis, Autoimmunity and Octapharma.
Marinos C. Dalakas focuses on Immunology, Antibody, Autoantibody, Pathology and Rituximab. His work often combines Immunology and Multifocal motor neuropathy studies. Eculizumab is closely connected to Immunotherapy in his research, which is encompassed under the umbrella topic of Antibody.
His research investigates the link between Pathology and topics such as Skeletal muscle that cross with problems in Inflammation, Alemtuzumab, Inclusion body myositis and HMGB1. The study incorporates disciplines such as B cell, Internal medicine, Autoimmune disease and Stiff person syndrome in addition to Rituximab. His Internal medicine research is multidisciplinary, relying on both Surgery and Oncology.
His primary scientific interests are in Immunology, Autoantibody, Myasthenia gravis, Rituximab and Autoimmunity. Immunotherapy, Antibody, Chronic inflammatory demyelinating polyneuropathy, Eculizumab and Neuroinflammation are the core of his Immunology study. His Autoantibody research includes themes of Anti-SSA/Ro autoantibodies, Pathology, Cytotoxicity, Epitope mapping and Epilepsy.
His Pathology study incorporates themes from Optic neuritis and Plasmapheresis. As a part of the same scientific family, Marinos C. Dalakas mostly works in the field of Myasthenia gravis, focusing on Dermatomyositis and, on occasion, Differential diagnosis, Muscle disease, Biopsy and Pathogenesis. His work deals with themes such as Randomized controlled trial, Surgery and Randomization, which intersect with Rituximab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Polymyositis and Dermatomyositis
Marinos C Dalakas;Reinhard Hohlfeld.
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
Marinos C. Dalakas.
The New England Journal of Medicine (1991)
A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis
Marinos C. Dalakas;Isabel Illa;James M. Dambrosia;Shawke A. Soueidan.
The New England Journal of Medicine (1993)
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.
Lori A. Love;Richard L. Leff;David D. Fraser;Ira N. Targoff.
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Marinos C. Dalakas;Isabel Illa;G.H. Pezeshkpour;Joseph P. Laukaitis.
The New England Journal of Medicine (1990)
Mitochondrial toxicity of antiviral drugs.
William Lewis;Marinos C. Dalakas.
Nature Medicine (1995)
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial
Richard A C Hughes;Peter Donofrio;Vera Bril;Marinos C Dalakas.
Lancet Neurology (2008)
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs
G K Bertsias;J P A Ioannidis;M Aringer;E Bollen.
Annals of the Rheumatic Diseases (2010)
Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle
Karl Poetter;He Jiang;Shahin Hassanzadeh;Stephen R. Master.
Nature Genetics (1996)
Inflammatory Muscle Diseases
Marinos C. Dalakas.
The New England Journal of Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: